黃 怡翔

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. Survival 25%
3. Taiwan 25%
4. Liver 21%
5. Hepatitis B virus 19%
6. Chronic Hepatitis B 18%
7. Liver Neoplasms 17%
8. Fibrosis 17%
9. Chronic Hepatitis C 16%
10. Antiviral Agents 16%
11. Radiofrequency Ablation 16%
12. Bilirubin 15%
13. Therapeutics 14%
14. Hepacivirus 13%
15. Hepatitis Delta Virus 12%
16. Propensity Score 12%
17. Albumins 11%
18. Hepatitis B 11%
19. Hepatitis B e Antigens 11%
20. Recurrence 10%
21. Liver Cirrhosis 9%
22. Neoplasms 9%
23. Hepatitis B Surface Antigens 9%
24. Hepatitis C 9%
25. End Stage Liver Disease 9%
26. Tumor Burden 8%
27. Serum 8%
28. Genotype 8%
29. Virus Diseases 8%
30. Hepatitis 7%
31. Fetal Proteins 7%
32. Sofosbuvir 7%
33. Sorafenib 7%
34. Fatty Liver 7%
35. Chemical and Drug Induced Liver Injury 6%
36. Portal Hypertension 6%
37. Radiofrequency Therapy 6%
38. Interferons 6%
39. BMS-790052 5%
40. Liver Diseases 5%
41. entecavir 5%
42. Hepatic Encephalopathy 5%
43. Nomograms 5%
44. Non-alcoholic Fatty Liver Disease 5%
45. Mortality 5%